Compare Natco Pharma with Dr. Reddys - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs DR. REDDYS LAB - Comparison Results

DR. REDDYS LAB 
   Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA DR. REDDYS LAB NATCO PHARMA/
DR. REDDYS LAB
 
P/E (TTM) x 15.5 21.6 71.7% View Chart
P/BV x 3.0 3.2 94.2% View Chart
Dividend Yield % 1.5 0.7 200.3%  

Financials

 NATCO PHARMA   DR. REDDYS LAB
EQUITY SHARE DATA
    NATCO PHARMA
Mar-18
DR. REDDYS LAB
Mar-19
NATCO PHARMA/
DR. REDDYS LAB
5-Yr Chart
Click to enlarge
High Rs1,0802,875 37.6%   
Low Rs6711,888 35.6%   
Sales per share (Unadj.) Rs592.1930.2 63.7%  
Earnings per share (Unadj.) Rs188.4117.4 160.5%  
Cash flow per share (Unadj.) Rs206.3185.8 111.1%  
Dividends per share (Unadj.) Rs8.2520.00 41.3%  
Dividend yield (eoy) %0.90.8 112.2%  
Book value per share (Unadj.) Rs833.6844.4 98.7%  
Shares outstanding (eoy) m36.90166.07 22.2%   
Bonus/Rights/Conversions ISESOP-  
Price / Sales ratio x1.52.6 57.8%   
Avg P/E ratio x4.620.3 22.9%  
P/CF ratio (eoy) x4.212.8 33.1%  
Price / Book Value ratio x1.12.8 37.2%  
Dividend payout %4.417.0 25.7%   
Avg Mkt Cap Rs m32,311395,496 8.2%   
No. of employees `0004.822.0 22.0%   
Total wages/salary Rs m3,25633,562 9.7%   
Avg. sales/employee Rs Th4,522.57,032.8 64.3%   
Avg. wages/employee Rs Th674.01,527.9 44.1%   
Avg. net profit/employee Rs Th1,439.0887.7 162.1%   
INCOME DATA
Net Sales Rs m21,848154,482 14.1%  
Other income Rs m4043,375 12.0%   
Total revenues Rs m22,252157,857 14.1%   
Gross profit Rs m9,28431,782 29.2%  
Depreciation Rs m66211,348 5.8%   
Interest Rs m154889 17.3%   
Profit before tax Rs m8,87222,920 38.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m0438 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,9203,858 49.8%   
Profit after tax Rs m6,95219,500 35.7%  
Gross profit margin %42.520.6 206.5%  
Effective tax rate %21.616.8 128.6%   
Net profit margin %31.812.6 252.1%  
BALANCE SHEET DATA
Current assets Rs m21,307111,101 19.2%   
Current liabilities Rs m5,92058,973 10.0%   
Net working cap to sales %70.433.7 208.7%  
Current ratio x3.61.9 191.0%  
Inventory Days Days7379 92.3%  
Debtors Days Days10794 113.1%  
Net fixed assets Rs m14,986101,245 14.8%   
Share capital Rs m369830 44.5%   
"Free" reserves Rs m30,353139,406 21.8%   
Net worth Rs m30,760140,236 21.9%   
Long term debt Rs m022,000 0.0%   
Total assets Rs m37,151224,656 16.5%  
Interest coverage x58.626.8 218.8%   
Debt to equity ratio x00.2 0.0%  
Sales to assets ratio x0.60.7 85.5%   
Return on assets %19.19.1 210.8%  
Return on equity %22.613.9 162.5%  
Return on capital %29.314.9 196.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m10,32288,673 11.6%   
Fx outflow Rs m2,97819,104 15.6%   
Net fx Rs m7,34369,569 10.6%   
CASH FLOW
From Operations Rs m4,63628,704 16.2%  
From Investments Rs m-11,155-7,727 144.4%  
From Financial Activity Rs m6,509-21,326 -30.5%  
Net Cashflow Rs m-18-314 5.7%  

Share Holding

Indian Promoters % 52.0 25.5 204.1%  
Foreign collaborators % 1.5 0.0 -  
Indian inst/Mut Fund % 7.8 5.4 145.2%  
FIIs % 16.6 35.3 47.1%  
ADR/GDR % 0.0 18.5 -  
Free float % 26.0 15.3 169.9%  
Shareholders   25,395 75,885 33.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   SHASUN PHARMA  WYETH LTD  ABBOTT INDIA  UNICHEM LAB  PROCTER & GAMBLE HEALTH  

Compare NATCO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slips Over 300 Points; Axis Bank & Tech Mahindra Top Losers(12:30 pm)

Share markets in India have extended early losses and are presently trading deep in the red. Barring consumer durables sector, all sectoral indices are trading in red with stocks in the telecom sector.

Related Views on News

NATCO PHARMA Announces Quarterly Results (1QFY20); Net Profit Down 21.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 21.1% YoY). Sales on the other hand came in at Rs 5 bn (down 8.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (4QFY19); Net Profit Down 59.8% (Quarterly Result Update)

May 28, 2019 | Updated on May 28, 2019

For the quarter ended March 2019, NATCO PHARMA has posted a net profit of Rs 1 bn (down 59.8% YoY). Sales on the other hand came in at Rs 5 bn (down 40.6% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

NATCO PHARMA Announces Quarterly Results (3QFY19); Net Profit Down 26.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (down 26.7% YoY). Sales on the other hand came in at Rs 6 bn (down 1.0% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (3QFY19); Net Profit Up 67.0% (Quarterly Result Update)

Feb 4, 2019 | Updated on Feb 4, 2019

For the quarter ended December 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 67.0% YoY). Sales on the other hand came in at Rs 39 bn (up 0.8% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

NATCO PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 115.2% (Quarterly Result Update)

Nov 12, 2018 | Updated on Nov 12, 2018

For the quarter ended September 2018, NATCO PHARMA has posted a net profit of Rs 2 bn (up 115.2% YoY). Sales on the other hand came in at Rs 5 bn (up 27.4% YoY). Read on for a complete analysis of NATCO PHARMA's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Sep 17, 2019 02:01 PM

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA - DIVIS LABORATORIES COMPARISON

COMPARE NATCO PHARMA WITH

MARKET STATS